Genetic Variant Showing a Positive Interaction With β-Blocking Agents With a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients: The Ser 447 -Stop Substitution in the Lipoprotein Lipase Gene
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background Lipoprotein lipase (LPL) is the rate-limiting enzyme in the lipolysis of triglyceride-rich lipoproteins, and the gene coding for LPL is therefore a candidate gene in atherogenesis. We previously demonstrated that two amino acid substitutions in LPL, the Asn 291 -Ser and the Asp 9 -Asn, are associated with elevated triglycerides and lower HDL cholesterol and are present with greater frequency in coronary artery disease (CAD) patients than in normolipidemic control subjects. Conversely, a third frequent mutation in this gene, the Ser 447 -Stop, is reported by some investigators to underlie higher HDL cholesterol levels and would represent a beneficial genetic variant in lipoprotein metabolism. We therefore sought conclusive evidence for these allegations by investigating the effects of the LPL Ser 447 -Stop mutation on LPL and hepatic lipase (HL) activity, HDL cholesterol, and triglycerides in a large group of CAD patients (n=820) with normal to mildly elevated total and LDL cholesterol levels. Methods and Results Carriers of the Ser 447 -Stop allele (heterozygotes and homozygotes) had significantly higher postheparin LPL activity ( P =.034), normal postheparin HL activity ( P =.453), higher HDL cholesterol levels ( P =.013), and lower triglyceride levels ( P =.044) than noncarriers. The influence of the Ser 447 -Stop allele on LPL activity was pronounced in patients using β-blockers ( P =.042) and not significant in those not using them ( P =.881), suggesting a gene-environment interaction between the Ser 447 -Stop mutation and β-blockers. Conclusions We conclude that the LPL Ser 447 -Stop mutation has a significant positive effect on LPL activity and HDL cholesterol and triglyceride levels and that certain subgroups of CAD patients carrying the Ser 447 -Stop mutation will have less adverse metabolic effects when placed on β-blockers. The LPL Ser 447 -Stop mutation therefore should have a protective effect against the development of atherosclerosis and subsequent CAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assmann, G., & Schulte, H. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90550-i · Cited by 872
Cited by
Kuivenhoven, J. A., Jukema, J. W., Zwinderman, A. H., de Knijff, P., McPherson, R., Bruschke, A. V. G., Lie, K. I., & Kastelein, J. J. P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380203 · Cited by 625
Self-citationMerkel, M., Eckel, R. H., & Goldberg, I. J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200015-jlr200 · Cited by 522
Wittrup, H. H., Tybjærg-Hansen, A., & Nordestgaard, B. G. (1999) · Circulation · doi:10.1161/01.cir.99.22.2901 · Cited by 344
Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation
Rip, J., Nierman, M. C., Ross, C. J., Jukema, J. W., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., & Kuivenhoven, J. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000219283.10832.43 · Cited by 157
Self-citationPostprandial lipemia as a cardiometabolic risk factor
Pirillo, A., Norata, G. D., & Catapano, A. L. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.909394 · Cited by 108
Metadata
- Authors
- Groenemeijer, B. E., Hallman, M. D., Reymer, P. W. A., Gagné, E., Kuivenhoven, J. A., Bruin, T., Jansen, H., Lie, K. I., Bruschke, A. V. G., Boerwinkle, E., Hayden, M. R., & Kastelein, J. J. P.
- Venue
- Circulation
- Published
- 1997-06-17
- Volume
- 95
- Issue
- 12
- Pages
- 2628-2635
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2013264580
- Cited by
- 137
- References
- 1
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic Variant Showing a Positive Interaction With β-Blocking Agents With a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients: The Ser 447 -Stop Substitution in the Lipoprotein Lipase Gene. https://app.cochat.ai/papers/10.1161/01.cir.95.12.2628
- The paper
- Groenemeijer, B. E., Hallman, M. D., Reymer, P. W. A., Gagné, E., Kuivenhoven, J. A., Bruin, T., Jansen, H., Lie, K. I., Bruschke, A. V. G., Boerwinkle, E., Hayden, M. R., & Kastelein, J. J. P. (1997). Genetic Variant Showing a Positive Interaction With β-Blocking Agents With a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients: The Ser 447 -Stop Substitution in the Lipoprotein Lipase Gene. Circulation. https://doi.org/10.1161/01.cir.95.12.2628
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.